Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition

The therapeutic benefits of immune checkpoint inhibitors (ICIs), which enable antitumor immune responses, can be tempered by unwanted immune-related adverse events (irAEs). Treatment recommendations stratified by irAE phenotype and immunohistopathological findings have only recently been proposed an...

Descripción completa

Detalles Bibliográficos
Autores principales: Henderson Berg, Meagan-Helen, del Rincón, Sonia Victoria, Miller, Wilson H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796266/
https://www.ncbi.nlm.nih.gov/pubmed/35086945
http://dx.doi.org/10.1136/jitc-2021-003551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796266/
https://www.ncbi.nlm.nih.gov/pubmed/35086945
http://dx.doi.org/10.1136/jitc-2021-003551

Ejemplares similares